<DOC>
	<DOCNO>NCT00670930</DOCNO>
	<brief_summary>This study aim investigate effect omalizumab number tissue eosinophils marker airway inflammation remodeling , include thickness lamina reticularis , moderate severe asthmatic persistent symptom evidence airway inflammation despite treatment inhaled corticosteroid long act beta-agonists . This study also investigate correlation systemic pulmonary inflammation , correlation clinical outcome change within tissue , assist future identification patient tissue eosinophilia response treatment , without need invasive bronchoscopy .</brief_summary>
	<brief_title>Efficacy Omalizumab Adults ( 18-60 Years Age ) With Moderate-Severe , Persistent Allergic Asthma , Despite Receiving Inhaled Corticosteroids Long Acting Beta-agonists</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients 1875 year age moderate severe persistent allergic asthma receive high dose inhale corticosteroid ( ≥800µg per day BDP equivalent ) regular long act betaagonist least 3 month prior screen With body weight 20 150kg serum total IgE level 30 700 IU/mL With ≥2 % eosinophilia induce sputum screen With postbronchodilator forced expiratory volume 1 second ( FEV1 ) ≥60 % predict With positive skin prick test ( diameter wheal ≥ 3 mm ) RAST test least one perennial aeroallergen ( eg . dust mite , cat/dog dander , cockroach ) , document within past 2 year demonstrate Visit 1 , patient expose regular basis ( day ) duration study . Patients 've asthma exacerbation 4 week prior randomization Current smoker , stop smoke within last 12 month smoke history &gt; 10 pack year History severe allergy food drug Previous treatment omalizumab Any patient consider unsuitable bronchoscopy , accord judgment investigator Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Asthma , adult , anti-immunoglobulin E ( IgE ) , omalizumab , airway inflammation , airway remodel , allergy</keyword>
</DOC>